Aramis Announces New Fragrance, Intuition, with Dwyane Wade as Global Ambassador
NEW YORK — Today, Aramis announces the launch of Intuition by Aramis, marking a new chapter for the legendary men's fragrance brand. Dwyane Wade will serve as Global Ambassador and the face of Intuition by Aramis, launching in August 2025, having collaborated closely with the brand on the campaign storytelling and creative expression.
Article content
Article content
Launched in 1963, Aramis became an industry leader in the men's fragrance and grooming category as the first men's prestige fragrance in the US. More than 60 years later, leveraging the brand's rich heritage and fragrance authority, Intuition by Aramis is inspired by the idea of a new kind of masculinity – EQ as well as IQ; sensitivity as well as strength; purpose as well as power. Wade is the embodiment of all these qualities, evolving from one of the most successful NBA shooting guards to a highly regarded multi-hyphenate: producer, philanthropist, advocate, and entrepreneur.
Article content
'I'm excited to join the Aramis family as a Global Ambassador and launch Intuition by Aramis this summer,' said Dwyane Wade. 'Aramis is a brand that aligns with my values, and Intuition reflects modern masculinity and confidence. Fragrance is all about how you present yourself to the world. Your scent is part of your vibe, and my new fragrance truly levels up your scent-game.'
Article content
'We couldn't be more excited to be announcing Intuition by Aramis with the incomparable Dwyane Wade,' said Justin Boxford, Global Brand President, Estée Lauder & Aramis. 'From family to fashion to philanthropy, Dwyane is a visionary and changemaker who is the epitome of modern masculinity. Through the reimagination of Aramis and the collaboration with Dwyane, we are able to honor the brand's incredible heritage while tapping into new consumers in the rapidly growing men's fragrance market.'
Article content
Intuition by Aramis, a woody, green neo-fougère, will launch in August 2025 at key global retailers and will retail for $95/50ml and $130/100ml.
Article content
Wade's inaugural Intuition campaign will debut across TV, print, digital, in-store and OOH.
Article content
About Aramis
In 1963, Aramis was created by Mrs. Estée Lauder, trailblazing entrepreneur and visionary founder of her eponymous cosmetics company, to be the most elegant men's cologne in the world. Refined and distinctive, with a classic masculinity and sophistication that would transcend time, Aramis was the first prestige men's fragrance to be sold in department stores around the world and quickly became an industry leader in the men's fragrance and grooming category.
Article content
Today, Aramis Fragrance is revitalized and reimagined for a new generation.
Article content
Follow Aramis on Instagram @AramisFragrances #ARAMISINTUITION.
Article content
About Dwyane Wade
Dwyane Wade is an entrepreneur with partnerships including Way of Wade, MISSION, Stance, BallerTV, Proudly, Versace, TMRW Sports, Wade Cellars, Thorne, and Jeeter. Wade has stakes in the Utah Jazz, Chicago Sky, Real Salt Lake, and Utah Royals ownership groups. The WY Network is Wade's digital show and podcast network, which includes hero show Time Out where you can find unfiltered basketball, lifestyle, and cultural conversations. Founder of 59th & Prairie Entertainment, he is an executive producer of Emmy and Oscar-winning projects. He is the New York Times bestselling author of A Father First, co-authored the New York Times bestselling children's book Shady Baby, and released his photographic memoir DWYANE in 2021. His Wade Family Foundation provides relief to marginalized communities in need. As an NBA player for sixteen seasons and primarily with the Miami Heat, he was selected as an NBA All-Star 13 times, won three NBA championships, and was named the 2006 NBA Finals Most Valuable Player. He is an Olympic Gold medalist, was named to the NBA's 75th Anniversary team as one of the 75 greatest players in NBA history and was inducted into the 2023 Naismith Memorial Basketball Hall of Fame. In 2024, Wade became the first Miami Heat player to receive a statue.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
31 minutes ago
- Globe and Mail
Amkor Technology to Announce Second Quarter 2025 Financial Results on July 28, 2025
Amkor Technology, Inc. (Nasdaq: AMKR), a leading provider of semiconductor packaging and test services, will issue its financial results for the second quarter of 2025 after the close of trading on the Nasdaq Global Select Market on Monday, July 28, 2025. Amkor management will host a conference call and webcast to review the results on Monday, July 28, 2025, at 5:00 p.m. Eastern Time (ET). To access the live audio webcast and the accompanying slide presentation, visit the Investor Relations section of Amkor's website, located at An archived replay of the webcast will be available after completion of the call. The live call can also be accessed by dialing 1-877-407-4019 or 1-201-689-8337. About Amkor Technology, Inc. Amkor Technology, Inc. is the world's largest US headquartered OSAT (outsourced semiconductor assembly and test) service provider. Since its founding in 1968, Amkor has pioneered the outsourcing of IC packaging and test services and is a strategic manufacturing partner for the world's leading semiconductor companies, foundries, and electronics OEMs. Amkor provides turnkey manufacturing services for the communication, computing, automotive and industrial and consumer markets, including smartphones, data centers, artificial intelligence, electric vehicles and wearables. Amkor's operational base includes production facilities, research and development centers, and sales and support offices located in key electronics manufacturing regions in Asia, Europe and the United States. For more information visit
Globe and Mail
31 minutes ago
- Globe and Mail
CoreWeave to Acquire Core Scientific
CoreWeave (NASDAQ: CRWV), the AI Hyperscaler™, and Core Scientific (NASDAQ: CORZ), a leading data center infrastructure provider, today announced that they have signed a definitive agreement under which CoreWeave will acquire Core Scientific in an all-stock transaction. Under the terms of the merger agreement, Core Scientific stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock based on a fixed exchange ratio. Following CoreWeave's successful IPO in March 2025, this acquisition will help CoreWeave verticalize its data center footprint to future-proof revenue growth and enhance profitability. Through this acquisition, CoreWeave will own approximately 1.3 GW of gross power across Core Scientific's national data center footprint 1 with an incremental 1 GW+ of potential gross power available for expansion. 'This acquisition accelerates our strategy to deploy AI and HPC workloads at scale,' said Michael Intrator, CoreWeave's Chief Executive Officer, Chairman of the Board, and co-founder. 'Verticalizing the ownership of Core Scientific's high-performance data center infrastructure enables CoreWeave to significantly enhance operating efficiency and de-risk our future expansion, solidifying our growth trajectory. Owning this foundational layer of our platform will enhance our performance and expertise as we continue helping customers unleash AI's full potential.' Strategic Benefits of CoreWeave's Acquisition Operational Efficiency: CoreWeave expects to generate significant cost savings through streamlining business operations and eliminating lease overhead. Greater Financing Flexibility: CoreWeave can pursue infrastructure financing strategies to finance committed capital expenditures, reducing its overall cost of capital. Power Ownership and Optionality: CoreWeave will gain greater control over a critical power footprint and optionality for future power capacity. Expanded Expertise: Core Scientific's data center development capabilities complement and augment CoreWeave's extensive expertise in power procurement, construction, and site management for infrastructure assets. "As our longstanding partner, CoreWeave has experienced firsthand the operational excellence we deliver and the value of the services we provide,' said Adam Sullivan, President and Chief Executive Officer of Core Scientific. 'Together with CoreWeave, we will be well-positioned to accelerate the availability of world-class infrastructure for companies innovating with AI while delivering the greatest value for our shareholders, who will be able to participate in the tremendous upside potential of the combined company." Transaction Details The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including regulatory approval and approval by Core Scientific stockholders. Upon closing and under the terms of the agreement, which has been approved by the board of directors of each company, Core Scientific stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock held. As of July 3, 2025, the agreed-upon exchange ratio implies a total equity value of approximately $9.0 billion. This is calculated on a fully diluted basis and based on CoreWeave's 5-day VWAP. This represents a $20.40 per share value based on the closing price of CoreWeave Class A common stock as of July 3, 2025, and a premium of approximately 66% to the unaffected Core Scientific closing share price of $12.30 on June 25, 2025. The final value will be determined at the time of transaction close. Upon close, CoreWeave expects Core Scientific's stockholders' ownership of the combined company will be less than 10%. Financial Impact Immediate elimination of over $10 billion of cumulative future lease overhead to be paid for existing contractual sites over the next 12 years. Leverage neutral impact to CoreWeave while opening access to diverse financing sources at a more attractive cost of capital. Including the elimination of the lease overhead, this deal adds $500 million of estimated fully ramped, annual run rate cost savings by the end of 2027 through streamlined operational focus. Potential to repurpose toward HPC usage or divest crypto mining business over the medium-term horizon. (1) Represents ~840 existing gross MW power supporting CoreWeave's HPC contracts and ~500 gross MW crypto mining data center power capacity Investor Call CoreWeave will hold an investor call on July 7, 2025, at 8:45 AM ET. The conference call will be accessible through a live webcast via CoreWeave's investor relations page ( A replay of the call will also be available on CoreWeave's investor relations page. Advisors Goldman Sachs & Co. LLC is acting as financial advisor, and Davis Polk & Wardwell LLP and Kirkland & Ellis LLP are acting as legal counsel to CoreWeave. Moelis & Company LLC and PJT Partners LP are acting as financial advisors, and Wachtell Lipton Rosen & Katz is acting as legal counsel to Core Scientific. About CoreWeave CoreWeave, the AI Hyperscaler™, delivers a cloud platform of cutting-edge software powering the next wave of AI. The company's technology provides enterprises and leading AI labs with cloud solutions for accelerated computing. Since 2017, CoreWeave has operated a growing footprint of data centers across the US and Europe. CoreWeave was ranked as one of the TIME100 most influential companies and featured on Forbes Cloud 100 ranking in 2024. Learn more at About Core Scientific Core Scientific is a leader in digital infrastructure for high-density colocation services and digital asset mining. We operate dedicated, purpose-built facilities for digital asset mining and are a premier provider of digital infrastructure, software solutions and services to our third-party customers. We employ our own large fleet of computers ('miners') to earn digital assets for our own account and to provide hosting services for large digital asset mining customers and we are in the process of allocating and converting a significant portion of our ten facilities in Alabama (1), Georgia (2), Kentucky (1), North Carolina (1), North Dakota (1), Oklahoma (1) and Texas (3) to support artificial intelligence-related workloads under a series of contracts that entail the modification of certain of our data centers to deliver next generation colocation services. We derive the majority of our revenue from earning digital assets for our own account ('self-mining'). To learn more, visit Important Information about the Transaction and Where to Find It In connection with the proposed transaction between CoreWeave, Inc. ('CoreWeave') and Core Scientific, Inc. ('Core Scientific'), CoreWeave and Core Scientific will file relevant materials with the U.S. Securities and Exchange Commission (the 'SEC'), including a registration statement on Form S-4 filed by CoreWeave that will include a proxy statement of Core Scientific that also constitutes a prospectus of CoreWeave. A definitive proxy statement/prospectus will be mailed to stockholders of Core Scientific. This communication is not a substitute for the registration statement, proxy statement or prospectus or any other document that CoreWeave or Core Scientific (as applicable) may file with the SEC in connection with the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF COREWEAVE AND CORE SCIENTIFIC ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the registration statement and the proxy statement/prospectus (when they become available), as well as other filings containing important information about CoreWeave or Core Scientific, without charge at the SEC's Internet website ( Copies of the documents filed with the SEC by CoreWeave will be available free of charge on CoreWeave's internet website at or by contacting CoreWeave's investor relations contact at investor-relations@ Copies of the documents filed with the SEC by Core Scientific will be available free of charge on Core Scientific's internet website at The information included on, or accessible through, CoreWeave's or Core Scientific's website is not incorporated by reference into this communication. Participants in the Solicitation CoreWeave, Core Scientific, their respective directors and certain of their respective executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and executive officers of Core Scientific is set forth in its proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on March 28, 2025 (and which is available at in its Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on February 27, 2025 (and which is available at and in its Form 8-K, which was filed with the SEC on May 16, 2025 (and which is available at Information about the directors and executive officers of CoreWeave is set forth in CoreWeave's Prospectus dated March 27, 2025, which was filed with the SEC on March 31, 2025 pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the Registration Statement on Form S-1, as amended (File No. 333-285512) (and which is available at These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct or indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials filed with the SEC when they become available. No Offer or Solicitation This communication is for informational purposes only and is not intended to, and shall not, constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Forward-Looking Statements This communication contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address future business and financial events, conditions, expectations, plans or ambitions, and often contain words such as 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words, but not all forward-looking statements include such words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. All such forward-looking statements are based upon current plans, estimates, expectations and ambitions that are subject to risks, uncertainties and assumptions, many of which are beyond the control of CoreWeave and Core Scientific, that could cause actual results to differ materially from those expressed in such forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: the completion of the proposed transaction on anticipated terms, or at all, and timing of completion, including obtaining regulatory approvals that may be required on anticipated terms and Core Scientific stockholder approval for the proposed transaction; anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the combined company's operations and other conditions to the completion of the proposed transaction, including the possibility that any of the anticipated benefits of the proposed transaction will not be realized or will not be realized within the expected time period; the ability of CoreWeave and Core Scientific to integrate their businesses successfully and to achieve anticipated synergies and value creation; potential litigation relating to the proposed transaction that could be instituted against CoreWeave, Core Scientific or their respective directors and officers; the risk that disruptions from the proposed transaction will harm CoreWeave's or Core Scientific's business, including current plans and operations and that management's time and attention will be diverted on transaction-related issues; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; rating agency actions and CoreWeave's and Core Scientific's ability to access short- and long-term debt markets on a timely and affordable basis; legislative, regulatory and economic developments and actions targeting public companies in the artificial intelligence, power, data center and crypto mining industries and changes in local, national or international laws, regulations and policies affecting CoreWeave and Core Scientific; potential business uncertainty, including the outcome of commercial negotiations and changes to existing business relationships during the pendency of the proposed transaction that could affect CoreWeave's and/or Core Scientific's financial performance and operating results; certain restrictions during the pendency of the proposed transaction that may impact Core Scientific's ability to pursue certain business opportunities or strategic transactions or otherwise operate its business; acts of terrorism or outbreak of war, hostilities, civil unrest, attacks against CoreWeave or Core Scientific and other political or security disturbances; dilution caused by CoreWeave's issuance of additional shares of its securities in connection with the proposed transaction; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the impacts of pandemics or other public health crises, including the effects of government responses on people and economies; global or regional changes in the supply and demand for power and other market or economic conditions that impact demand and pricing; changes in technical or operating conditions, including unforeseen technical difficulties; development delays at CoreWeave and/or Core Scientific data center sites, including any delays in the conversion of such sites from crypto mining facilities to high-performance computing sites; those risks described in the section titled 'Risk Factors' in CoreWeave's Prospectus dated March 27, 2025, filed with the SEC on March 31, 2025 pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to the Registration Statement on Form S-1, as amended (File No. 333-285512), Item 1A of CoreWeave's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 15, 2025 and subsequent reports on Forms 10-Q and 8-K; those risks described in Item 1A of Core Scientific's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 7, 2025, Item 1A of Core Scientific's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 27, 2025 and subsequent reports on Forms 10-Q and 8-K; and those risks that will be described in the registration statement on Form S-4 and accompanying prospectus, available from the sources indicated above. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the proxy statement/prospectus that will be included in the registration statement on Form S-4 that will be filed with the SEC in connection with the proposed transaction. While the list of factors presented here is, and the list of factors to be presented in the registration statement on Form S-4 will be, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. You should not place undue reliance on any of these forward-looking statements as they are not guarantees of future performance or outcomes; actual performance and outcomes, including, without limitation, CoreWeave's or Core Scientific's actual results of operations, financial condition and liquidity, and the development of new markets or market segments in which CoreWeave or Core Scientific operate, may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Neither CoreWeave nor Core Scientific assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Neither future distribution of this communication nor the continued availability of this communication in archive form on CoreWeave's or Core Scientific's website should be deemed to constitute an update or re-affirmation of these statements as of any future date.
Globe and Mail
31 minutes ago
- Globe and Mail
Ambac Financial Group and Oaktree announce an extension to the stock purchase agreement for the Financial Guarantee business
Ambac Financial Group, Inc. (NYSE: AMBC) ('Ambac') today announced the extension from July 3, 2025, to December 31, 2025 of the term of the stock purchase agreement relating to the sale of its legacy financial guarantee businesses—Ambac Assurance Corporation ('AAC') and Ambac UK ('AUK')—to funds managed by Oaktree Capital Management, L.P. ('Oaktree') for $420 million in cash. Both Ambac and Oaktree remain fully committed to closing the transaction. Oaktree continues to work with the Wisconsin Office of the Commissioner of Insurance (the 'OCI') to satisfy its remaining closing conditions and obtain final regulatory approval. 'We continue to await final regulatory approval for this strategic transaction and remain aligned with Oaktree and confident in completing the sale,' said Claude LeBlanc, President and CEO of Ambac. 'This transaction remains the capstone to our transformation into a pure-play specialty P&C insurance platform, and we look forward to closing it as soon as practicable.' 'Oaktree has been actively working towards, and is committed to, obtaining the final regulatory approval from the OCI to close on the acquisition of AAC and AUK,' said Oaktree Managing Director Greg Share. 'We look forward to closing this transaction once such approval is received.' In addition to the extension, Ambac and Oaktree have agreed to a conversion right for the warrant to purchase Ambac common stock that Oaktree is receiving at the closing of the transaction. Ambac and Oaktree have also agreed to arrangements with respect to Ambac's existing lease obligations and on the treatment of certain expenses allocated to AAC prior to the closing of the transaction. Full details of the amendment will be disclosed in a Current Report on Form 8-K to be filed by Ambac with the SEC today. About Ambac Ambac Financial Group, Inc. ('Ambac') is an insurance holding company headquartered in New York City. Ambac's core business is a growing specialty P&C distribution and underwriting platform. Ambac's common stock trades on the New York Stock Exchange under the symbol 'AMBC'. Ambac is committed to providing timely and accurate information to the investing public, consistent with our legal and regulatory obligations. To that end, we use our website to convey information about our businesses, including the anticipated release of quarterly financial results, quarterly financial, statistical, and business-related information. For more information, please go to The Amended and Restated Certificate of Incorporation of Ambac contains substantial restrictions on the ability to transfer Ambac's common stock. Subject to limited exceptions, any attempted transfer of common stock shall be prohibited and void to the extent that, as a result of such transfer (or any series of transfers of which such transfer is a part), any person or group of persons shall become a holder of 5% or more of Ambac's common stock or a holder of 5% or more of Ambac's common stock increases its ownership interest. About Oaktree Oaktree is a leader among global investment managers specializing in alternative investments, with $203 billion in assets under management as of March 31, 2025. The firm emphasizes an opportunistic, value-oriented, and risk-controlled approach to investments in credit, equity, and real estate. The firm has more than 1,200 employees and offices in 25 cities worldwide. For additional information, please visit Oaktree's website at Forward-Looking Statements In this press release, statements that may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as 'estimate,' 'project,' 'plan,' 'believe,' 'anticipate,' 'intend,' 'planned,' 'potential' and similar expressions, or future or conditional verbs such as 'will,' 'should,' 'would,' 'could,' and 'may,' or the negative of those expressions or verbs, identify forward-looking statements. We caution readers that these statements are not guarantees of future performance. Forward-looking statements are not historical facts but instead represent only our beliefs regarding future events, which may by their nature be inherently uncertain and some of which may be outside our control. These statements may relate to plans and objectives with respect to the future, among other things which may change. We are alerting you to the possibility that our actual results may differ, possibly materially, from the expected objectives or anticipated results that may be suggested, expressed or implied by these forward-looking statements. Important factors that could cause our results to differ, possibly materially, from those indicated in the forward-looking statements include, among others, those discussed under 'Risk Factors' in our most recent SEC filed quarterly or annual report.
